Tirzepatide Use Resulted in Clinically Meaningful Weight Reduction in Individuals With Obesity or Overweight: 12-Month Real-World Results
- Design
- Retrospective cohort
- Drugs
- Tirzepatide
- Assessment
- Facts extracted automatically · reviewed by Carrie Schluter, Nov 5, 2026 · added Nov 6, 2026
This study was added automatically, and its details were extracted by machine rather than read off the paper by a person. Carrie Schluter has reviewed the record, but that review did not re-extract those details, so the collection still publishes no population match, weight-loss explanation, study tier, findings, population or funding details for it: a check of automatically extracted details found too many errors to show them as fact. The abstract below is the source as retrieved.
01Source
The source, as retrieved
Abstract
[AIMS] This study assessed the real-world effectiveness of tirzepatide in commercially insured individuals without diabetes, eligible for obesity medications (OMs), including glucagon like-peptide-1 receptor agonist (GLP-1 RA)-naïve individuals (i.e., no GLP-1 RA prescription during the 12-month pre-index period) and GLP-1 RA-experienced individuals. [METHODS] This retrospective, observational cohort study used Optum's de-identified Market Clarity Data (Optum Market Clarity). Adults with ≥ 1 prescription claim for tirzepatide between November 2023 and March 2024, with continuous medical/pharmacy enrollment for ≥ 12 months pre-index and post-index and available pre- and post-index data were included. Baseline demographics, clinical characteristics, and treatment effectiveness (change from baseline in weight, body mass index, and cardiometabolic risk factors) were assessed among OM-eligible individuals who were persistent on tirzepatide for ≥ 12 months. [RESULTS] The GLP-1 RA-naïve and experienced cohorts included 230 individuals (mean age: 49.5 years, 72.2% female) and 123 individuals (mean age: 48.9 years, 81.3% female), respectively, who were persistent on tirzepatide for 12 months with documented pre- and post-index weight measurements. At baseline, more than 85% of individuals in each cohort had ≥ 1 obesity-related complication, most commonly dyslipidemia, hypertension, and prediabetes. At 12 months post-index, the GLP-1 RA-naïve cohort achieved a mean weight reduction of 19.3%, while the GLP-1 RA-experienced cohort achieved a mean weight reduction of 13.1%. [CONCLUSIONS] After 12 months of persistent tirzepatide use, individuals experienced clinically meaningful weight reduction, comparable to outcomes reported in clinical trials. These real-world findings were observed both in GLP-1 RA-naïve and experienced individuals.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Nov 1, 2026 | 42951303 first ingestion |
| owner-review | Nov 6, 2026 | reviewed_by set to Carrie Schluter (2026-11-05) on the owner's own confirmation. The assessment is unchanged and still the auto-classifier's, so its extracted values stay withheld under the 2026-10-18 decision. |
| reextract | Nov 6, 2026 | manufacturer: 'Eli Lilly, Lilly' -> 'Eli Lilly'. Q-043: manufacturer and drug_details.dose re-extracted by auto-classifier-v1.2. manufacturer no longer reads companies named only in the authors' conflicts statement (IN-062) and refuses a multi-company roster; dose is tied to the GLP-1 agent by name, never reads a concentration, and records a multi-dose design whole. Every other value is carried forward unchanged. Owner decision IN-064 option 1, 2026-11-06. |
| pubmed | Nov 8, 2026 | 42951303 duplicate matched on doi |